scispace - formally typeset
C

Charles Kilo

Researcher at Washington University in St. Louis

Publications -  86
Citations -  6393

Charles Kilo is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Diabetes mellitus & Vascular permeability. The author has an hindex of 40, co-authored 86 publications receiving 6274 citations.

Papers
More filters
Journal ArticleDOI

Hyperglycemic Pseudohypoxia and Diabetic Complications

TL;DR: Several lines of evidence support the likelihood that the increased cytosolic ratio of free NADH/NAD+ caused by hyperglycemia, referred to as pseudohypoxia, is a characteristic feature of poorly controlled diabetes that mimics the effects of true hypoxia on vascular and neural function and plays an important role in the pathogenesis of diabetic complications.
Journal ArticleDOI

A glucagon-secreting alpha-cell carcinoma of the pancreas.

TL;DR: A fourth type of humoral activity, that of hyperglucagonism, associated with an alpha-cell carcinoma of the pancreatic islets is reported, probable that cases of this disorder are at present unrecognized, or classified otherwise.
Journal ArticleDOI

Muscle Capillary Basement Membrane Changes Related to Aging and to Diabetes Mellitus

TL;DR: Observations on diabetics suggest that basement membrane width is probably normal in most subjects prior to the onset of carbohydrate intolerance and demonstrate that both the magnitude and incidence of basement membrane thickening increase with longer known duration of carbohydrates intolerance.
Journal ArticleDOI

Prevention of Hemodynamic and Vascular Albumin Filtration Changes in Diabetic Rats by Aldose Reductase Inhibitors

TL;DR: Observations indicate that early diabetes-induced hemodynamic changes and increased vascular albumin permeation and urinary albumin excretion are aldose reductase-linked phenomena, and increases in blood flow may reflect impaired contractile function of smooth muscle cells in resistance arterioles.
Journal ArticleDOI

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

TL;DR: Combining aliskiren with ramipril provided a greater reduction in msDBP than either drug alone in patients with diabetes and hypertension, despite large increases in PRC in all treatment groups.